The CRISPR era is here and we’re proud to be at the forefront. Thank you AtlanticLIVE for inviting our CEO Samarth Kulkarni to the #AtlanticHealth Summit to discuss how CRISPR is pioneering a new era of medicine with potential applications for a range of serious diseases. #CRISPRTX

We had the honor of attending the Life Science Cares Boston Impact Breakfast earlier this week. We’re proud to support their efforts in making a positive impact on our local community by volunteering and raising awareness about poverty and inequality. #CRISPRTX

On April 4th at 10am ET, our CEO Dr. Samarth Kulkarni Samarth Kulkarni will join The Atlantic's Health Summit to discuss the future of gene-editing technology. Learn more and register here: theatlantic.com/live/health-su… #AtlanticHealth

We’re pleased to announce the acceptance of an oral presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting. Learn more here: bit.ly/4ahQVui #ASGCT2024

March 24th is Lipoprotein(a) Awareness Day. Did you know that Lp(a) is a genetic factor that increases the risk for both heart disease and stroke? Learn more at: bit.ly/48PrpLi #KnowLpa

We're pleased to invite Christian Rommel, Ph.D., to join our Board of Directors. His extensive experience accelerating innovation and advancing drug candidates across modalities will be invaluable as we continue to advance our platform and pipeline: bit.ly/3wQlSXH

On #RareDiseaseDay , our CEO Dr. Samarth Kulkarni Samarth Kulkarni joined CNBC’s Power Lunch discussing the science of gene editing and opportunities to efficiently scale the use of #CRISPR technology for a range of serious diseases. Watch here: bit.ly/48KgJhg

During International Women’s Day, CRISPR Therapeutics celebrates the achievements of women globally. Thank you to the women at the forefront of gene editing who are leading the charge to revolutionize the way we treat diseases. #IWD2024 #InspireInclusion

#RareDiseaseDay brings a global focus on efforts to raise awareness and support for individuals living with rare conditions. Learn more about this initiative and how you can get involved here: bit.ly/3GtUpe1

Today, we announced our fourth quarter and full year earnings results. Read more about our recent highlights and outlook: bit.ly/3UNvRqz #CRISPR #CRISPR TX

#Breaking : The European Commission approves CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for #SickleCellDisease and #BetaThalassemia for the European Union. Learn more: bit.ly/3IifYkR

The U.S. FDA approves the CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for transfusion-dependent beta thalassemia. Learn more: bit.ly/47yIgS1

We are excited to highlight our strategic priorities and outlook for 2024 as we enter our next phase of growth. Learn more here: bit.ly/3NT2yie #CRISPR #CRISPR TX

We are pleased to share that we will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference next week. We hope you can join us for the presentation on Tuesday, January 9 at 2:15pm PT in San Francisco: bit.ly/4aGXB5M #CRISPR #CRISPR TX

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the conditional approval of the CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for #SickleCellDisease and #BetaThalassemia .

#Breaking : The U.S. FDA approves the CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for #SickleCellDisease . Learn more: bit.ly/4apMw9p

Today, we provided an update on our immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T cell product candidates and we announced expansion into autoimmune disease. Learn more here: bit.ly/4a8zpsM

The UK Medicines and Healthcare products Regulatory Agency approves the CRISPR/Cas9 gene-edited treatment for #SickleCellDisease & #BetaThalassemia in Great Britain. This is a historic milestone arising out of our collaboration with Vertex. Learn more: crisprtx.com

It was an exciting day as Dr. PK Morrow, our Chief Medical Officer, presented preclinical data on our investigational programs for the treatment of cardiovascular disease in two oral sessions at the American Heart Association Scientific Sessions. Learn more: bit.ly/47oCkLX #AHA23

Today, we announced our third quarter earnings results. Read more about our recent highlights and outlook: bit.ly/470K2Ms